(IN BRIEF) Itepekimab, developed by Sanofi and Regeneron, met its primary endpoint in the AERIFY-1 phase 3 study for COPD, showing a 27% reduction in moderate or severe exacerbations at 52 weeks. However, the AERIFY-2 study did not achieve the … Read the full press release →
Posted in Business, Financial, France, Government, Healthcare, Industrial, Investment, Management, Marketing, News, Pharma & Biotech, Science, Technology
Tagged adverse events, AERIFY-1, AERIFY-2, Chronic obstructive pulmonary disease, clinical trials, COPD, COVID-19, drug efficacy, Exacerbations, IL33, Itepekimab, moderate exacerbations, monoclonal antibody, partnership, phase 3 study, Regeneron, regulatory authorities, research and development, Sanofi, severe exacerbations, therapeutic development